Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting - A disproportionality analysis.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15711
Abstract: AIM Recent case reports have suggested that sodium-glucose co-transporter 2 inhibitors (SGLT2i) may interact with statins to increase their risk of myotoxicity. We assessed the risk of myotoxicity reporting associated with concomitant use of SGLT2i… read more here.
Keywords: reporting; risk myotoxicity; concomitant use; sglt2i ... See more keywords